Biocon is currently trading at RS 372.75, up by 0.70 points or 0.19% from its previous close of RS 372.05 on the BSE.

The stock opened at RS 378.65 and recorded a high of RS 383.45 and a low of RS 371.80 during the session. A total of 49,912 shares have been traded so far.

The BSE ‘A’ group stock with a face value of RS 5 registered a 52-week high of RS 424.95 on 18-Nov-2025 and a 52-week low of RS 290.80 on 03-Mar-2025. Over the last one week, the share has moved between RS 393.20 and RS 366.25. The company currently holds a market capitalization of RS 56,257.47 crore.

Promoter shareholding stands at 54.45%, while Institutions and Non-Institutions hold 28.71% and 16.83% respectively.

Meanwhile, Biocon’s wholly owned subsidiary Biocon Pharma has received USFDA approval for its ANDA for Everolimus Tablets for Oral Suspension in 2 mg, 3 mg, and 5 mg strengths. The drug is indicated for treatment of adult and pediatric patients with Tuberous Sclerosis Complex (TSC) suffering from Subependymal Giant Cell Astrocytoma (SEGA), and as adjunct therapy for TSC-associated partial-onset seizures. The approval is expected to further enhance Biocon’s portfolio of integrated drug products.

Biocon is recognized as India’s largest and Asia’s leading biotechnology company, with a core focus on biopharmaceuticals and research services. The company operates as a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases worldwide.